KAPA Kairos Pharma Limited: שווי עסקי להכנסות

Kairos Pharma Ltd (KAPA) production capacities are focused on testing new molecules and preparing for mass production. The enterprise value-to-revenue ratio visualizes market expectations, where 0.00 reflects the latest value of the metric. Since success in oncology depends on science rather than economics, the company is striving to expand its pipeline to overcome tumor resistance and capture the market.
KAPA (Kairos Pharma Ltd): פילוחים אנליטיים ודוחות לפי אינדיקטורים

This indicator compares the total enterprise value to annual revenue, excluding the impact of debt obligations to identify the true market overvaluation of the asset. By analyzing the enterprise value-to-revenue ratio, an investor can determine whether the price growth of Kairos Pharma Ltd (KAPA) is justified by real success in the commercialization of oncology drugs or if it is a speculative impulse preceding a price correction for the biotech issuer.